Drug intelligence / Profile preview

BNH 102

Development stage: Unknown
Lead developer: BnH Research
Modality: Small Molecules
Administration: Oral

Overview

BNH 102 is a clinical-stage drug candidate developed by BnH Research for the treatment of post-traumatic stress disorder (PTSD). The drug's mechanism of action involves the reopening of cortical or synaptic plasticity, a biological process intended to facilitate the extinction of traumatic memories and promote neural recovery. BNH 102 is currently in Phase 1 clinical development, having successfully completed preclinical safety and efficacy evaluations.

Beyond the preview

Go deeper on BNH 102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNH 102.

Explore the full profile